Hermes Medical Solutions & Vanderbilt University Announce an Exclusive License and Commercialization Agreement for the OLINDA / EXM® Dosimetry Application
Stockholm, Sweden and Nashville, Tennessee, U.S. - October 9th 2015
Hermes Medical Solutions (HMS) by Sofia Bertling COO and Vanderbilt University (Vanderbilt) by Professor Michael Stabin announced today the signature of an exclusive license and commercialization agreement for the new dosimetry application OLINDA / EXM® to be distributed by HMS.
The OLINDA / EXM® application is widely used in the radiopharmaceutical industry and research community for internal dose calculations of radiopharmaceuticals. The new version has been enhanced and includes new human models and nuclides.
HMS will continue the development, regulatory, manufacturing and commercial leadership of OLINDA / EXM®.
“OLINDA / EXM® is in line with HMS focus on individualized treatment planning and will facilitate patient dose decisions”, says Sofia Bertling, COO at HMS and Professor Michael Stabin.
About Vanderbilt University
Vanderbilt University, located in Nashville, Tennessee, U.S., is a private research university and medical center founded 1873. The University is top-ranked in several areas including its Department of Radiology and Radiological Sciences which is a leader in Nuclear Medicine Dosimetry.
OLINDA / EXM® is a registered trademark of Vanderbilt University, Nashville, Tennessee, U.S.A.
About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.
Director Strategic Marketing